PT3079715T - Uma mistura de péptidos - Google Patents

Uma mistura de péptidos

Info

Publication number
PT3079715T
PT3079715T PT148281488T PT14828148T PT3079715T PT 3079715 T PT3079715 T PT 3079715T PT 148281488 T PT148281488 T PT 148281488T PT 14828148 T PT14828148 T PT 14828148T PT 3079715 T PT3079715 T PT 3079715T
Authority
PT
Portugal
Prior art keywords
peptide mixture
peptide
mixture
Prior art date
Application number
PT148281488T
Other languages
English (en)
Portuguese (pt)
Inventor
Amund Eriksen Jon
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of PT3079715T publication Critical patent/PT3079715T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001164GTPases, e.g. Ras or Rho
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
PT148281488T 2013-12-09 2014-12-09 Uma mistura de péptidos PT3079715T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13196333 2013-12-09

Publications (1)

Publication Number Publication Date
PT3079715T true PT3079715T (pt) 2018-08-02

Family

ID=49765823

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148281488T PT3079715T (pt) 2013-12-09 2014-12-09 Uma mistura de péptidos

Country Status (24)

Country Link
US (4) US9775892B2 (enExample)
EP (5) EP3363458A3 (enExample)
JP (2) JP6781403B2 (enExample)
KR (1) KR20160097290A (enExample)
CN (1) CN105980403A (enExample)
AU (2) AU2014363643B2 (enExample)
BR (1) BR112016013138A2 (enExample)
CA (1) CA2933126A1 (enExample)
CL (4) CL2016001405A1 (enExample)
CY (1) CY1120578T1 (enExample)
DK (1) DK3079715T3 (enExample)
ES (1) ES2682038T3 (enExample)
HR (1) HRP20181213T1 (enExample)
HU (1) HUE039840T2 (enExample)
IL (1) IL246007B2 (enExample)
LT (1) LT3079715T (enExample)
MX (1) MX2016007429A (enExample)
PL (1) PL3079715T3 (enExample)
PT (1) PT3079715T (enExample)
RS (1) RS57623B1 (enExample)
RU (1) RU2016127327A (enExample)
SG (2) SG10201811172PA (enExample)
SI (1) SI3079715T1 (enExample)
WO (1) WO2015086590A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture
CN106414493A (zh) 2014-05-06 2017-02-15 塔格瓦克斯公司 包含突变的ras肽和化疗剂的肽疫苗
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
AU2018288386A1 (en) * 2017-06-22 2020-02-06 New South Wales Health Pathology Adoptive T cell therapy 2
CA3103983A1 (en) * 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
JP2021534752A (ja) * 2018-08-22 2021-12-16 フレッド ハッチンソン キャンサー リサーチ センター Kras抗原またはher2抗原を標的とする免疫療法
GB2596461B (en) 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
WO2021009633A1 (en) * 2019-07-12 2021-01-21 Massey University Synthetic chromatin vaccine
US12453774B2 (en) 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
KR102515083B1 (ko) 2020-12-24 2023-03-29 부산대학교 산학협력단 폴더블 페로브스카이트 태양전지 및 이의 제조 방법
EP4293043A4 (en) * 2021-02-10 2025-09-10 Shanghai Genbase Biotechnology Co Ltd EPITOPE PEPTIDE OF THE RAS G13D MUTANT AND T LYMPHOCYTE RECEPTOR RECOGNIZING THE RAS G13D MUTANT
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
EP4522192A2 (en) * 2022-05-12 2025-03-19 The Johns Hopkins University Neoantigen vaccines for cancer prevention
JP2025538524A (ja) * 2022-11-22 2025-11-28 エリクサージェン セラピューティクス,インコーポレイティド 癌免疫療法のための抗原

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
PL1760089T3 (pl) 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
CN101448848B (zh) * 2006-03-27 2013-12-04 全球免疫股份有限公司 Ras突变及其相关组合物和方法
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9775892B2 (en) 2013-12-09 2017-10-03 Targovax Asa Peptide mixture
CN106414493A (zh) 2014-05-06 2017-02-15 塔格瓦克斯公司 包含突变的ras肽和化疗剂的肽疫苗

Also Published As

Publication number Publication date
BR112016013138A2 (pt) 2018-01-16
US10335473B2 (en) 2019-07-02
HRP20181213T1 (hr) 2018-10-19
JP2020023525A (ja) 2020-02-13
CL2018000226A1 (es) 2018-06-22
US20170189515A1 (en) 2017-07-06
EP3079715B1 (en) 2018-06-13
AU2014363643A1 (en) 2016-07-14
AU2014363643B2 (en) 2019-01-03
KR20160097290A (ko) 2016-08-17
US20180021419A1 (en) 2018-01-25
JP6781403B2 (ja) 2020-11-04
LT3079715T (lt) 2018-08-27
RS57623B1 (sr) 2018-11-30
EP3363458A2 (en) 2018-08-22
EP3363457A1 (en) 2018-08-22
US10456457B2 (en) 2019-10-29
IL246007B1 (en) 2023-01-01
CY1120578T1 (el) 2019-07-10
CN105980403A (zh) 2016-09-28
SG10201811172PA (en) 2019-01-30
WO2015086590A2 (en) 2015-06-18
WO2015086590A3 (en) 2015-07-30
US10596239B2 (en) 2020-03-24
MX2016007429A (es) 2016-11-11
CL2018000238A1 (es) 2018-06-22
HUE039840T2 (hu) 2019-02-28
JP2017502081A (ja) 2017-01-19
US20160331820A1 (en) 2016-11-17
EP3369432A1 (en) 2018-09-05
AU2019201937A1 (en) 2019-04-11
SI3079715T1 (en) 2018-08-31
CA2933126A1 (en) 2015-06-18
SG11201604644QA (en) 2016-07-28
PL3079715T3 (pl) 2018-11-30
EP3079715A2 (en) 2016-10-19
CL2018000232A1 (es) 2018-06-22
IL246007A (en) 2016-07-31
RU2016127327A (ru) 2018-01-23
AU2019201937B2 (en) 2020-05-28
EP3363458A3 (en) 2018-11-07
CL2016001405A1 (es) 2017-03-24
US9775892B2 (en) 2017-10-03
ES2682038T3 (es) 2018-09-18
EP3357505A1 (en) 2018-08-08
US20170326218A1 (en) 2017-11-16
DK3079715T3 (en) 2018-09-17
IL246007B2 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
IL246007A (en) Peptide mixture
IL242005B (en) A peptide compound
GB201317990D0 (en) A conncetor
ZA201600729B (en) Peptides
GB201315751D0 (en) Analogues
GB2519432B (en) A Fungicide mixture
ZA201504986B (en) Peptide
PT3061771T (pt) Novo péptido unido a quatro epitopos ctl
ZA201504987B (en) Peptide
GB201315130D0 (en) Peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides
GB201305465D0 (en) Novel peptides
GB201311648D0 (en) A novel glass-lonomer cement
GB201318505D0 (en) Project carsign brand
GB201322749D0 (en) Cyclic peptide
GB201308191D0 (en) Peptide product
GB201308193D0 (en) Peptide product
GB201319398D0 (en) A footgauge
GB201313662D0 (en) A footgauge
GB201309977D0 (en) A sausepan
GB201301539D0 (en) A Smogzy